What Oncocyte (IMDX) Said on Its Q3 Earnings Call
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Insight Molecular Diagnostics (IMDX) expects to respond before a January 2027 deadline to the U.S. Food and Drug Administration’s request for more information about its GraftAssureDx kidney transplant test, executives said on the company’s third-quarter earnings call. President
Directly affected
- IMDX Insight Molecular Diagnostics
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Insight Molecular Diagnostics belongs to, so it often moves with news about it.
- IDXX IDEXX Laboratories+30.8% 14d
IDEXX Laboratories is a peer of Insight Molecular Diagnostics in in vitro and in vivo diagnostic substances; rivals often move on the same news.
- LNTH Lantheus Holdings+1.3% 30d
Lantheus Holdings is a peer of Insight Molecular Diagnostics in in vitro and in vivo diagnostic substances; rivals often move on the same news.
- NEOG Neogen-6.5% 30d
Neogen is a peer of Insight Molecular Diagnostics in in vitro and in vivo diagnostic substances; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| IMDX | +34.05% | +24.32% | base | after close | after close | after close | after close |
| XLV | +0.52% | -0.04% | base | after close | after close | after close | after close |
| IDXX | -0.56% | -0.37% | base | after close | after close | after close | after close |
| LNTH | -0.12% | -0.49% | base | after close | after close | after close | after close |
| NEOG | +7.26% | +2.94% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
What Oncocyte (IMDX) Said on Its Q3 Earnings Call Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| IDXX | three days earlier | -0.37% | final price |
| IDXX | five days earlier | -0.56% | final price |
| IMDX | three days earlier | +24.32% | final price |
| IMDX | five days earlier | +34.05% | final price |
| LNTH | three days earlier | -0.49% | final price |
| LNTH | five days earlier | -0.12% | final price |
| NEOG | three days earlier | +2.94% | final price |
| NEOG | five days earlier | +7.26% | final price |
| XLV | three days earlier | -0.04% | final price |
| XLV | five days earlier | +0.52% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Idexx Laboratories (IDXX) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 53 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Idexx Laboratories (IDXX) (held by a dependent child), worth $15,001 - $50,000 on 11 Sep 2026. That is 67 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Idexx Laboratories (IDXX) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 74 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Gilbert Cisneros sold Lantheus Holdings (LNTH), worth $1,001 - $15,000 on 15 Oct 2026. That is 33 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Gilbert Cisneros sold Lantheus Holdings (LNTH), worth $1,001 - $15,000 on 14 Oct 2026. That is 34 days before publication. Filed 10 Nov 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “What Oncocyte (IMDX) Said on Its Q3 Earnings Call” looks
12 out of 100
“What Oncocyte (IMDX) Said on Its Q3 Earnings Call” scores 12 out of 100. The score uses 1 sources.